
|Videos|July 26, 2022
Fezolinetant making waves for VMS
Author(s)Morgan Ebert, Managing Editor
Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Top FDA approvals in women's health in 2025
2
No evidence links menopause hormone therapy to dementia risk
3
Opioid use in pregnancy raises maternal and infant risks
4
Broader genetic testing improves breast cancer risk detection
5











